Trial Profile

Phase III clinical trial of TO-203 - Evaluation of efficacy and safety in pediatric patients with HDM-induced allergic rhinitis -

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jul 2018 Results published in the Allergy
16 Feb 2018 According to a ALK-Abello media release, based on the data from this trial Japanese Ministry of Health, Labour and Welfare,has approved to expand the use of ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients.
24 Mar 2017 According to a company media release, ALK announced that its partner for Japan, Torii Pharmaceutical Co., Ltd., has submitted an application to the Japanese Ministry of Health, Labour and Welfare, seeking to expand the use of ALK's house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients. The new application is based on results from this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com